Trevena Initiates Targeted Proof-of-Concept Study to Evaluate TRV045 as a Potential Treatment for Epilepsy and Other CNS Disorders
March 07, 2023 07:00 ET
|
Trevena, Inc.
CHESTERBROOK, Pa., March 07, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Announces Publication of OLINVYK Respiratory Physiology Study In ANESTHESIOLOGY
February 14, 2023 08:00 ET
|
Trevena, Inc.
OLINVYK demonstrated a reduced impact on respiratory depression compared to IV morphine, among elderly/overweight subjects Study consistent with prior results that suggest OLINVYK provides a...
Trevena Enrolls First Subject in TRV045 Proof-of-Concept Trial Evaluating S1PR Mechanism of Action and Target Engagement
January 09, 2023 07:00 ET
|
Trevena, Inc.
New Phase 1 clinical study designed to build on nonclinical evidence of anti-inflammatory signaling and potential disease-modifying effect of TRV045 in the treatment of epilepsy and other CNS...
Trevena Announces Poster Presentations of TRV045 Nonclinical Epilepsy Data, and OLINVYK Clinical Neurocognitive and GI Data, at Recent Medical Meetings
December 08, 2022 07:00 ET
|
Trevena, Inc.
TRV045 data reflected reduced seizure burden in nonclinical models of acute epilepsy presented at American College of Neuropsychopharmacology (ACNP) Annual Meeting OLINVYK poster...
Trevena Regains Compliance with Nasdaq Listing Requirements
November 29, 2022 07:00 ET
|
Trevena, Inc.
CHESTERBROOK, Pa., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena, Inc. Announces $8.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
November 16, 2022 08:00 ET
|
Trevena, Inc.
CHESTERBROOK, Pa., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) ("Trevena" or the "Company"), a biopharmaceutical company focused on the development and commercialization of novel...
Trevena Announces Reverse Stock Split
November 09, 2022 16:01 ET
|
Trevena, Inc.
CHESTERBROOK, Pa., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Announces Completion of Phase 1 Study for TRV045, Novel S1P Receptor Modulator
November 09, 2022 07:02 ET
|
Trevena, Inc.
TRV045 demonstrated a favorable tolerability profile with no reported SAEs and no lymphopenia Nonclinical study showed anti-inflammatory signaling, suggesting a potential disease-modifying effect of...
Trevena Reports Third Quarter 2022 Results and Provides Business Update
November 09, 2022 07:00 ET
|
Trevena, Inc.
OLINVYK commercialization progresses with Vizient contract and receipt of CMS outpatient pass-through reimbursement Positive Phase 1 topline results for TRV045, a novel S1P receptor modulator; no...
Trevena to Release Third Quarter 2022 Financial Results on November 9, 2022
November 07, 2022 07:00 ET
|
Trevena, Inc.
CHESTERBROOK, Pa., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...